Q4 FY2026 Quarterly Result Highlights of Kalyan Jewellers, Abbott India, Syrma SGS, Nuvama Wealth and Medi Assist

Kalyan Jewellers exceptional Q4 FY26 results: PAT soaring 118%, revenue up 66% YoY

• Kalyan Jewellers reported exceptional Q4 FY26 results, with consolidated net profit soaring 118% year-on-year to ₹410 crore and revenue rising 66% to ₹10,275 crore, driven by strong wedding demand and 129 new showroom launches.

Key Highlights for Q4 FY26 (January–March 2026):

• Net Profit: Increased 118.28% to ₹409.50 crore compared to ₹187.61 crore in Q4 FY25.
• Revenue: Grew to ₹10,274.94 crore from ₹6,181.53 crore, a 66.22% increase Y-o-Y.
• EBITDA: Rose 77.6% to ₹781.85 crore.
• Candere Performance: The online vertical saw revenue growth of 160% and achieved profitability in the second half of FY26.
• Regional Performance: Strong performance was noted globally, with international revenue growing 43% to ₹1,157 crore and profit rising 105% to ₹29 crore.
• Full Year FY26 Summary:
• Total Revenue: Rose 43% to ₹35,742.9 crore, up from ₹25,045.1 crore in FY25.
• Total PAT: Increased 86% to ₹1,350.4 crore, up from ₹714.8 crore in the previous year.
• Expansion: The company continues to focus on expansion, with plans for further showroom addition.

Abbott India Q4 FY2026 Results: Net Profit up 6.7%, Margins expanded.

• Abbott India posted a 6.7% YoY increase in net profit to ₹3.95 billion for Q4 FY26 results, supported by a significant expansion in EBITDA margins to 28.09% and a 6.25% rise in revenue to ₹17 billion.
• The company’s revenue from operations rose by 6.54% year-on-year to ₹1,709.51 crore, with EBITDA increasing by over 10%.
• Key highlights for the quarter and fiscal year ending March 2026:
• Net Profit: ₹394.93 crore for Q4 FY26, up 7.6% YoY.
• Revenue: ₹1,709.51 crore, up 6.54% YoY.
• EBITDA: ₹556.44 crore, up 10.28% YoY.
• Full Year FY26: Net profit grew 9.7% YoY to ₹1,552.02 crore, with revenue up 8.1% to ₹6,929.05 crore. The company, known for products like Thyronorm, Udiliv, and Cipralex, experienced margin expansion (reaching around 28%) despite facing pressure on operating costs.

Syrma SGS Tech strong Q4 FY26 results: Revenue up 56%, PAT 67% YoY 

• Syrma SGS Technology reported strong Q4 FY26 results, with consolidated net profit surging by up to 67% YoY to ₹119 crore and revenue increasing 56% to ₹1,476.8 crore, driven by robust demand in key electronics verticals. The company announced a final dividend of ₹1.50 per share.
• Key Financial Highlights (Q4 FY26 – Consolidated):
• Net Profit: ₹119.2 crore, up 67% from ₹71.45 crore loss in Q4 FY25, or ₹101 crore in some reports (up 55%).
• Revenue from Operations: ₹1,476.8 crore, up 56% YoY.
• EBITDA: ₹186 crore, up 43% YoY.
• EBITDA Margin: Remained strong around 12%.
• Full Year FY26 Performance:
• Revenue: Increased 27% to ₹4,856.9 crore, exceeding ₹1,200 crore in exports.
• Net Profit: Surged 87% to ₹345.8 crore.
• Key Takeaways:
• Growth Drivers: Increased demand in industrial, automotive, and consumer electronics verticals, along with improved operational efficiency.Expansion: The company continues to benefit from ‘Make in India’ initiatives and strong execution, with a 60% stake acquisition in Elcome for ₹235 crore.
• Stock Reaction: Positive. Shares hit a record high of ₹1,188 on the NSE on May 12, 2026.

Medi Assist Healthcare Services strong Q4 FY26 Result: Revenue up 28% and PAT doubles

• Medi Assist Healthcare Services reported a strong Q4 FY26, with consolidated net profit soaring to ₹53.44 crore, up 148.10% YoY from ₹21.54 crore in Q4 FY25. 
• Revenue from operations grew 28.13% YoY to ₹241.99 crore, driven by high volumes and integration of recent acquisitions.
• Key Financial Highlights for Q4 FY26:
• Net Profit: ₹53.44 crore (vs ₹21.54 crore in Q4 FY25).
• Revenue: ₹241.99 crore (up 28.13% YoY).
• EBITDA Margin: Improved to 19.9% compared to 17.1% in Q2 FY26.
• Profit Before Tax (PBT): ₹27.90 crore.
• Growth Drivers: Increased policy administration volumes, improved operational efficiency, and low finance costs.
• Key Developments:The company witnessed significant growth from the integration of the acquired Paramount Health Services & Insurance TPA Private Limited.
• For the full fiscal year 2026 (FY26), revenue from operations rose by 25.1% YoY to ₹904.77 crore.
• Stock Reaction: Positive. The stock gained over 5% over two sessions following Q4 results.

Nuvama Wealth Q4 FY2026: PAT up 5.3%, Revenue up 13%

• Nuvama Wealth Management reported a 5.3% YoY rise in consolidated net profit for the March quarter of FY26 at ₹269.15 crore, compared with ₹255.41 crore in the corresponding quarter last year, supported by growth across its diversified financial services businesses.
• Total revenue from operations increased 13.3% YoY to ₹1,269.14 crore in Q4FY26, from ₹1,119.81 crore a year ago.
• For FY26, consolidated profit rose 5.5% YoY to ₹1,041.04 crore, against ₹986.17 crore in FY25.
• The board approved an interim dividend of ₹14 per share and fixed May 15, 2026, as the record date. The dividend will be paid on or before June 9, 2026.
• Ashish Kehair, Managing Director and Chief Executive Officer of Nuvama Group, said FY26 remained challenging amid macro uncertainty, volatile markets, regulatory changes and heightened competition, but the company delivered resilient growth through disciplined execution and strong client focus.
• He said the company continued to invest in talent, AI, technology and product capabilities in its wealth management business, while asset services attracted flows from both domestic and international clients despite market volatility. Kehair added that the company maintained its equity market share in capital markets and continued to expand its fixed income business through stronger origination and distribution capabilities.
• The management said the company remains well positioned for sustained long-term growth, backed by its diversified platform, governance-led approach and strong client relationships.
• Share Reaction: Negative.